These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16608120)

  • 41. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.
    Barbosa MD; Vielmetter J; Chu S; Smith DD; Jacinto J
    Clin Immunol; 2006 Jan; 118(1):42-50. PubMed ID: 16260183
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cell-based reporter gene assay for therapy-induced neutralizing antibodies to interferon-beta in multiple sclerosis.
    Martins TB; Rose JW; Gardiner GL; Kusukawa N; Husebye D; Hill HR
    J Interferon Cytokine Res; 2013 Feb; 33(2):52-7. PubMed ID: 23153300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is there or is there not a place for anti-interferon antibodies in the decision making of multiple sclerosis treatment optimisation?
    Grigoriadis N; Deretzi G; Artemis N; Tascos N; Milonas I
    Neurol Sci; 2006 Sep; 27 Suppl 5():S355-7. PubMed ID: 16998719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
    Cludts I; Meager A; Thorpe R; Wadhwa M
    J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.
    Gneiss C; Tripp P; Ehling R; Khalil M; Lutterotti A; Egg R; Mayringer I; Künz B; Berger T; Reindl M; Deisenhammer F
    J Neuroimmunol; 2006 May; 174(1-2):174-9. PubMed ID: 16556466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
    Francis GS; Rice GP; Alsop JC;
    Neurology; 2005 Jul; 65(1):48-55. PubMed ID: 16009884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D; Sellebjerg F; Sorensen PS
    Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta.
    Lawrence N; Oger J; Aziz T; Palace J; Vincent A
    J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1236-9. PubMed ID: 12933925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
    Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
    J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.
    Lundkvist M; Greiner E; Hillert J; Fogdell-Hahn A
    Mult Scler; 2010 Jul; 16(7):796-800. PubMed ID: 20534645
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
    McKay F; Schibeci S; Heard R; Stewart G; Booth D
    J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of resistance to biologic therapies with reference to IFN-β.
    Farrell RA; Marta M; Gaeguta AJ; Souslova V; Giovannoni G; Creeke PI
    Rheumatology (Oxford); 2012 Apr; 51(4):590-9. PubMed ID: 22258390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
    Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
    Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of an interferon-beta1a product.
    Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
    Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimising MS disease-modifying therapies: antibodies in perspective.
    Giovannoni G
    J Neurol; 2004 Sep; 251 Suppl 5():v30-v35. PubMed ID: 15549353
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.
    Hermanrud C; Ryner M; Luft T; Jensen PE; Ingenhoven K; Rat D; Deisenhammer F; Sørensen PS; Pallardy M; Sikkema D; Bertotti E; Kramer D; Creeke P; Fogdell-Hahn A;
    J Immunol Methods; 2016 Mar; 430():1-9. PubMed ID: 26779831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Guidelines on use of anti-IFN-B antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-B antibodies in multiple sclerosis.
    Burks JS; Noronha A
    Eur J Neurol; 2007 Jun; 14(6):e8-9; author reply e10-1. PubMed ID: 17539931
    [No Abstract]   [Full Text] [Related]  

  • 59. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy.
    Hesse D; Sørensen PS
    Eur J Neurol; 2007 Aug; 14(8):850-9. PubMed ID: 17662004
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients.
    Gibbs E; Oger J
    J Interferon Cytokine Res; 2008 Dec; 28(12):713-23. PubMed ID: 18937545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.